ITP and AA: Our current understanding and what the future might hold
EHA Learning Center. Novartis D. Jul 19, 2017; 192923
Topic: Section 1: Clinical hematology Benign
Delivered by Novartis
Delivered by Novartis
Login now to access Regular content available to all registered users.

Access to EHA Members only content is an EHA membership benefit.
Click here to join EHA or renew your membership here.


Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
- Review the advances in disease understanding over the last decade
- Overview challenges associated with the treatment of patients with ITP and AA
- Provide practical management guidance and share best practice on current treatment options for ITP and AA
- Provide an update on recent clinical trial data in ITP and severe AA to guide best treatment practice
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings